Eisai Co., Ltd.
FY2025 Q3 Financial Results
Consolidated revenue for FY2025 Q3 was JPY 619.9 billion (up 103.1% YoY), operating income was JPY 54.5 billion (98.3% YoY), and net income attributable to owners of parent was JPY 41.8 billion (91.9% YoY).
Key Figures
- Consolidated Revenue: JPY 619.9 billion (103.1% YoY)
- Operating Income: JPY 54.5 billion (98.3% YoY)
- Net Income Attributable to Owners of Parent: JPY 41.8 billion (91.9% YoY)
AI要約
Summary of Financial Performance
Consolidated revenue for FY2025 Q3 was JPY 619.9 billion, an increase of 3.1% compared to the same period last year. Operating income was JPY 54.5 billion, a decrease of 1.7% YoY, while net income attributable to owners of parent was JPY 41.8 billion, down 8.1% YoY. The revenue growth was primarily driven by increased sales of the Alzheimer's treatment "Lecanemab," anticancer agent "Lenvima," and insomnia treatment "Duvieo." R&D expenses declined YoY due to a reassessment of development projects and cost efficiencies.
Segment Performance and Financial Position
The pharmaceutical business is divided into five regions: Japan, Americas, China, EMEA, and East Asia & Global South, recording a total revenue of JPY 610.1 billion, up 7.2% YoY. Particularly strong sales were seen in the Americas and China. On the financial position, total assets increased 7.2% from the previous fiscal year-end to JPY 1.4862 trillion, and total liabilities grew 9.6% to JPY 570.6 billion. No share buybacks were conducted, and the dividend is planned at JPY 160 per share.
Trends in Consolidated Revenue (JPY billion)
Trends in Consolidated Operating Income (JPY billion)
Trends in Net Income Attributable to Owners of Parent (JPY billion)
Revenue by Reported Segment (JPY billion)
Major Product Revenues (JPY billion) FY2025 Q3 Cumulative
Eisai Co., Ltd.
Company overview · Stock price · Financial data · All IR
